Selective Inhibition of Bruton’s Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors

  1. Sousa, B.B.
  2. de Almeida, C.R.
  3. Barahona, A.F.
  4. Lopes, R.
  5. Martins-Logrado, A.
  6. Cavaco, M.
  7. Neves, V.
  8. Carvalho, L.A.R.
  9. Labaõ-Almeida, C.
  10. Coelho, A.R.
  11. Bento, M.L.
  12. Lopes, R.M.R.M.
  13. Oliveira, B.L.
  14. Castanho, M.A.R.B.
  15. Neumeister, P.
  16. Deutsch, A.
  17. Vladimer, G.I.
  18. Krall, N.
  19. Joaõ, C.
  20. Corzana, F.
  21. Seixas, J.D.
  22. Fior, R.
  23. Bernardes, G.J.L.
Revue:
ACS Pharmacology and Translational Science

ISSN: 2575-9108

Année de publication: 2022

Volumen: 5

Número: 11

Pages: 1156-1168

Type: Article

DOI: 10.1021/ACSPTSCI.2C00163 GOOGLE SCHOLAR lock_openAccès ouvert editor
Dépôt institutionnel: lock_openAccès ouvert Editor

Objectifs de Développement Durable